To The Moon

Suzhou, 29 October, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KT-939 has recently received the review approval of the International Nomenclature Cosmetic Ingredient (the “INCI”) by the International Cosmetic Ingredient Nomenclature Committee with assigned Mono ID of 39815. KT-939 is a tyrosinase inhibitor under development by the Company, effectively inhibiting the melanin production with antioxidant and anti-inflammatory effects. If melanocytes produce an excessive amount of melanin, it may lead to skin pigmentation problems. Tyrosinase is a key rate-limiting enzyme in the synthesis of melanin, and inhibiting its activity can curb the production of melanin from the source. The previous enzymology and cellular melanoge

Suzhou, July 10, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that after receiving the designation for its in-house developed KX-826 from the International Nomenclature Cosmetic Ingredient (the “INCI”), the Company’s cosmetics with KX-826 as the main ingredient was officially launched into the international market recently. The first product is the topical anti-hair loss solution for androgenetic alopecia (the “AGA”).  The Company will further explore the efficacy of KX-826 in the field of AGA and acne, actively enrich the product lines, increase market promotion to target users and meet customer requirements under different usage scenarios. The Company is of the view that the launch of the New Product will provide a solid stream of revenue and cash

Suzhou, June 5, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KX-826 has recently received the International Nomenclature Cosmetic Ingredient (the “INCI”) review approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine. INCI names are systemic names recognized worldwide for the identification of cosmetic ingredients and are cited by product labeling regulations in many countries. The assignation would facilitate the global launch of the Company's functional cosmetics with KX-826 as the main ingredient. About Kintor Pharmaceutical Limited Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and c

Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.  The Clinical Trial is aimed to evaluate the efficacy and safety of KX-826 tincture 1.0% for the topical treatment of male adults with AGA in China. The Company’s preclinical studies have shown that the KX-826 tincture 1.0% has significantly increased the retention concentration of the tincture on h

2024 American Association of Cancer Research Annual Meeting (AACR 2024) will be held from April 5-10, 2024, in San Diego, United States. As the focal point of the cancer research community globally, countless latest scientific and medical studies in tumor field are first published here every year. In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized. The abstracts are available on AACR’s official website. Abstracts： GT0486（mTORC1/2） T

Suzhou, 13 March, 2024 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announces that Kintor and its cooperative partner had published an article named MYC Induces CDK4/6 Inhibitors Resistance by Promoting pRB1 Degradation in a subsidiary journal of Nature—Nature Communications (Impact factor: 16.6). Nature Communications is one of the top journals in biology field and is classified as Q1 in several categories, representing a leading research level in the world. The study shows that target c-Myc molecular glue compound has great potential, which could provide more directions for overcoming resistance issues of CDK4/6 inhibitors in various tumor fields. Issue This

Suzhou, October 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the results of the Phase Ib/II clinical trial of ALK-1 antibody GT90001 combined with PD-1 antibody nivolumab in the treatment of advanced hepatocellular carcinoma (HCC) were published online by the well-known journal BMC Medicine (Impact factor: 11.806). The results showed that this combination regimen is well-tolerated and has promising anti-tumor activity in patients with recurrent advanced HCC, with a confirmed overall response rate (ORR) of 30% and a remarkable long-tail effect. https://doi.org/10.1186/s12916-023-03098-w HCC is a common pathological type of liver cancer. The

Suzhou, August 28, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma” or “the company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2023 interim results and released an update on its recent business highlights.       2023 Interim Results Highlights ● Kintor Pharma has steadily advanced the global clinical development, with the dermatology pipeline achieving several milestones. The company has completed the patient enrollment in the Phase III clinical trial of KX-826 for male androgenetic alopecia (AGA) in China, and the top-line data is expected to be released in the fourth quarter of 2023. The Phase III clinical trial of KX-826 for female AGA in China and the Phase II

Suzhou, July 19, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the “Long-term Safety Trial”) of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today. The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023.  The Long-term Safety Trial is a multi-center, open-label Phase III clinical trial, which involves a total of 16 clinical research centers in China, with P

Suzhou, May 11, 2023 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatment of male androgenetic alopecia (“AGA”) in the US has been completed successfully. The results are statistically and clinically meaningful, and demonstrated a favorable safety profile. The company is preparing for subsequent FDA meetings on the results of the Phase II clinical trial, and intends to commence Phase III clinical trial in the US/globally. Results of the Phase II clinical trial showed that KX-826 promotes hair growth compared to baseline and demonstrated statistical and clinically meaningful as measured b